Home › Burkitt Lymphoma › Georgia › Augusta
Burkitt Lymphoma clinical trials in Augusta, GA
4 studies for Burkitt Lymphoma are looking for participants at sites in and around Augusta (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
- Augusta University Medical Center, Augusta
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
RecruitingPhase 3
- Augusta University Medical Center, Augusta
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RecruitingPhase 3
- Augusta University Medical Center, Augusta
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
RecruitingPhase 1
- Augusta Cancer Center, Augusta
Burkitt Lymphoma trials in other cities
- Houston, TX21 studies
- Milwaukee, WI16 studies
- Philadelphia, PA16 studies
- New York City, NY14 studies
- Chicago, IL14 studies
- Cincinnati, OH12 studies
- Atlanta, GA12 studies
- Seattle, WA11 studies
- Boston, MA10 studies
- Durham, NC10 studies
- Aurora, CO10 studies
- Kansas City, MO10 studies
Other studies in Augusta
- Acute Myeloid Leukemia10 studies
- Ovarian Cancer8 studies
- Endometrial Cancer7 studies
- Cancer (all types)7 studies
- Sickle Cell Disease5 studies
- Breast Cancer5 studies
- Myasthenia Gravis4 studies
- Blood Cancers4 studies
- Diffuse Large B-Cell Lymphoma4 studies
- Chronic Myeloid Leukemia4 studies
- Non-Hodgkin Lymphoma4 studies
- Cervical Cancer4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.